Science

01 July 2023 - 01 July 2025

VIDEC (Visualizing Death Inducing Protein Complexes)

01 January 2023 - 30 June 2025

ZeNeuroid: Human-based Neural Organoid Network for Parkisons Drug Discovery

01 December 2022 - 30 November 2025

ZeNeuroid: Human-based Neural Organoid Network for Drug Discovery

The project will use patient derived-iPSC and CRISPR-edited human IPSC to develop a novel three-dimensional microfluidic system for drug discovery.

01 October 2022 - 30 September 2027

EdiGenT – New Prime Editing and non-viral delivery strategies for Gene Therapy

The EdiGenT consortium will work to develop a new generation of more efficient gene correction tools based on the CRISPR/Cas9 system, and non-viral delivery strategies for gene therapy.

01 March 2022 - 01 March 2023

Kit Digital

Eleva Group has assisted ZeClinics in the installation of a Customer Relationship Management (CRM).

01 January 2022 - 30 June 2023

ZeBYTE – Platform to predict the effect of drugs based on the use of zebrafish and artificial intelligence

ZeBYTE aims at using artificial intelligence technologies along the whole target discovery process.

01 August 2021 - 01 August 2023

REMODEL – pREcise gene delivery for advanced disease MODELing

A cutting-edge gene-editing platform to generate complex disease models to test innovative therapeutic approaches.

01 April 2021 - 31 March 2024

ROBO-FISH – Automated high-throughput oncology drug screening in zebrafish using robotics and AI

The ROBO-FISH consortium will develop and validate injection and imaging robots to automate oncology drug screening in zebrafish to mimic human disease.

01 December 2020 - 30 November 2023

CARDIOMYO – An integrated HTS platform for the discovery of new therapeutics against cardiomyopathies

CARDIOMYO combines three complementary approaches: 1) high content phenotypic in vitro cardiac assays 2) a novel in vivo cardiovascular phenotyping using zebrafish and 3) drug discovery chemistry

01 September 2020 - 31 August 2023

NanoDIRE-CT – Use of nanobodies for targeted therapy against tumor stem cells

Our purpose is to isolate nanobodies that bind cancer stemm cells and have a direct cytotoxic effect on them, or could act as carriers of cytotoxic drugs specifically towards them.

01 September 2020 - 31 August 2023

NanoDIRE-CT: Breakthroughs in the Last Year of ZeClinics and Vall d’Hebron Collaboration

01 January 2020 - 31 December 2023

SCilS – Studying Ciliary Signaling in Development and Disease

SCilS is training a new generation of scientists to characterise ciliopathies, an increasingly important and diverse class of inherited diseases.

01 January 2020 - 31 December 2024

REANIMA – New-generation cardiac therapeutic strategies directed to the activation of endogenous regenerative mechanisms

REANIMA aims to deliver new therapies for heart regeneration, thereby reverting the conditions that lead to heart failure.

01 October 2019 - 30 September 2023

ZENITH – ZEbrafish Neuroscience Interdisciplinary Training Hub

The EU-funded ZENITH project is preparing a new generation of scientists for interdisciplinary collaboration on pressing neuroscience challenges utilising the zebrafish model system.

01 June 2019 - 31 May 2021

ZeNewCardio – Discovering Heart Regeneration Therapies Through Zebrafish

We propose the development of a high-throughput preclinical platform using the zebrafish model to find suitable treatments for heart regeneration after ischemia.

01 December 2018 - 31 May 2021

InnoTCM – Innovative Ways of Profiling Traditional Chinese Medicinal Herb Extracts Through Zebrafish

The concept of the InnoTCM project is to apply an innovative approach to profiling the TCM herb extracts by using Zebrafish as a model organism in High Throughput Screening (HTS) manner.